GSK takes up option on Five Prime respiratory targets
US biotech Five Prime Therapeutics (Nasdaq: FPRX) says that UK pharma major GlaxoSmithKline (LSE: GSK) has exercised its option to take an exclusive license to the intellectual property related to a target under the respiratory diseases research collaboration between the companies, triggering a $1.5 million license payment to Five Prime.
The news, released on Thursday, triggered a 3.65% rise to $44.29 in Five Prime shares, and the stock moved up to $44.68 on Friday.
“GSK’s decision to exercise the option to license Five Prime intellectual property with respect to a specific respiratory target further demonstrates the productivity and versatility of Five Prime’s unique platform to identify novel targets in a wide range of major diseases,” said Lewis "Rusty" Williams, president and chief executive of Five Prime, adding: “This is one of several potential targets that Five Prime has identified under the research collaboration with GSK, which have the potential to result in novel medicines for the treatment of respiratory disease.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze